483
Views
0
CrossRef citations to date
0
Altmetric
Research Article

SCN1A, SCN2A and SCN3A Gene Polymorphisms and Responsiveness to Antiepileptic Drugs: A Multicenter Cohort Study and Meta-Analysis

, , , , &
Pages 1153-1166 | Published online: 16 Jul 2013

References

  • Kwan P , SchachterSC, BrodieMJ. Drug-resistant epilepsy. N. Engl. J. Med.365 , 919–926 (2011).
  • Remy S , BeckH. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain19(Pt 1) , 18–35 (2006).
  • Schmidt D , LöscherW. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr.9(2) , 47–52 (2009).
  • Löscher W . Mechanisms of drug resistance:. Epileptic Disord.7(Suppl. 1) , S3–S9 (2005).
  • Payandeh J , ScheuerT, ZhengN et al. The crystal structure of a voltage-gated sodium channel. Nature 475 , 353–358 (2007).
  • Catterall WA . Voltage-gated sodium channels at 60: structure, function, and pathophysiology. J. Physiol.1 , 2577–2589 (2012).
  • Eijkelkamp N , LinleyJE, BakerMD et al. Neurological perspectives on voltage-gated sodium channels. Brain 135(Pt 9) , 2585–2612 (2012).
  • Ohashi J , TokunagaK. The expected power of genome-wide linkage disequilibrium testing using single nucleotide polymorphism markers for detecting a low-frequency disease variant. Ann. Hum. Genet.66(Pt 4) , 297–306 (2002).
  • Senior K . Gene variants affect response to antiepileptic drugs. Lancet Neurol.4(5) , 276–277 (2005).
  • Mantegazza M , CuriaG, BiaginiG et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9 , 413–424 (2010).
  • Zuliani V , FantiniM, RivaraM. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr. Top. Med. Chem.12 , 962–970 (2012).
  • Mantegazza M , CuriaG, BiaginiG et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9 , 413–424 (2010).
  • Tate SK , DepondtC, SisodiyaSM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15) , 5507–5512 (2005).
  • Tate SK , SinghR, HungCC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16(10) , 721–726 (2006).
  • Heinzen EL , YoonW, TateSK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80(5) , 876–883 (2007).
  • Krikova EV , Val‘dmanEA, AvakianGN et al. Association study of the SCN1 gene polymorphism and effective dose of lamotrigine. Zh. Nevrol. Psikhiatr. Im. S S Korsakova 109(10) , 57–62 (2009).
  • Zimprich F , StogmannE, BonelliS et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49 , 1108–1109 (2008).
  • Hung CC , ChangWL, HoJL et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13(2) , 159–169 (2012).
  • Zhou BT , ZhouQH, YinJY et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin. Exp. Pharmacol. Physiol. 39(4) , 379–384 (2012).
  • Zhou BT , ZhouQH, YinJY et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2‑year longitudinal clinical follow-up. CNS Neurosci. Ther. 18(7) , 566–572 (2012).
  • Abe T , SeoT, IshitsuT et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66(2) , 304–307 (2008).
  • Kwan P , PoonWS, NgHK et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet. Genomics 18(11) , 989–998 (2008).
  • Jang SY , KimMK, LeeKR et al. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J. Korean Med. Sci. 24(1) , 62–68 (2009).
  • Lakhan R , KumariR, MisraUK et al. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol. 68(2) , 214–220 (2009).
  • Sánchez MB , HerranzJL, LenoC et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 19(2) , 93–101 (2010).
  • Kumari R , LakhanR, GargRK et al. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J. Hum. Genet. 17(Suppl. 1) , S32–S40 (2011).
  • Manna I , GambardellaA, BianchiA et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52(5) , e40–e44 (2011).
  • Kumari R , LakhanR, KumarS et al. SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie95(6) , 1350–1353 (2013).
  • Haerian BS , BaumL, TanHJ et al. SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics13(13) , 1477–1485 (2012).
  • Saw SH . The Population of Peninsular Malaysia. Singapore University Press, National University of Singapore (1988).
  • Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia22 , 489–501 (1981).
  • Panayiotopoulos CP . The new ILAE report on terminology and concepts for organization of epileptic seizures: a clinician‘s critical view and contribution. Epilepsia52 , 2155–2160 (2011).
  • Kwan P , ArzimanoglouA, BergAT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies. Epilepsia 51(6) , 1069–1077 (2010).
  • Wang TY , WangL, ZhangJH et al. A simplified universal genomic DNA extraction protocol suitable for PCR. Genet. Mol. Res. 10(1) , 519–525 (2011).
  • Campanella JJ , SmalleyJV. A minimally invasive method of piscine tissue collection and an analysis of long-term field-storage conditions for samples. BMC Genet.7 , 32 (2006).
  • Gabriel S , ZiaugraL, TabbaaD. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr. Protoc. Hum. Genet.2 , 2–12 (2009).
  • Guo Y , BaumLW, ShamPC et al. Two-stage genome-wide association study identifies variants in CAMSAP1L1 as susceptibility loci for epilepsy in Chinese. Hum. Mol. Genet. 21(5) , 1184–1189 (2012).
  • Schaid DJ , JacobsenSJ. Biased tests of association: comparisons of allele frequencies when departing from Hardy–Weinberg proportions. Am. J. Epidemiol.149 , 706–711 (1999).
  • Bax L Yu LM, Ikeda N et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med. Res. Methodol.6 , 1–11 (2006).
  • Dupont WD , PlummerWD. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials19 , 589–601 (1998).
  • Spencer CC , SuZ, DonnellyP et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 5 , e1000477 (2009).
  • Kwan P , BrodieMJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5) , 314–319 (2000).
  • Rosenberg G . The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci.64 , 2090–2103 (2007).
  • Chateauvieux S , MorceauF, DicatoM et al. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. pii , 479364 (2010).
  • Gamble CL , WilliamsonPR, MarsonAG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst. Rev.25(1) , CD001031 (2006).
  • Marson AG , WilliamsonPR, CloughH et al. Epilepsy monotherapy trial group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 43 , 505–513 (2002).
  • Schmidt D , LöscherW. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia46 , 858–877 (2005).
  • Dequeker E , RamsdenS, GrodyWW, StenzelTT, BartonDE. Quality control in molecular genetic testing. Nat. Rev. Genet.2 , 717–723 (2001).

▪ Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.